1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
144.27 USD   +0.71%
07:14aINSIDER SELL : Moderna
MT
06/26Moderna Seeks Swissmedic's Approval Extension For COVID-19 Jab Against Omicron
MT
06/25Pfizer says tweaked COVID-19 shots boost omicron protection
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11

05/17/2022 | 08:55am EDT

By Will Feuer


The Food and Drug Administration expanded the authorization of Pfizer Inc.'s Covid-19 booster shot to kids ages 5 through 11 years old.

While Covid-19 tends to be less severe in kids than in adults, more kids have been getting sick and hospitalized with the disease amid the spread of the omicron variant, FDA Commissioner Dr. Robert Califf said.

"If your child is eligible for the Pfizer-BioNTech Covid-19 Vaccine and has not yet received their primary series, getting them vaccinated can help protect them from the potentially severe consequences that can occur, such as hospitalization and death," he said.

On Jan. 3, the FDA authorized Pfizer and BioNTech SE's Covid-19 booster shot for kids ages 12 through 15.


Write to Will Feuer at Will.Feuer@wsj.com


(END) Dow Jones Newswires

05-17-22 1055ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.32% 134.04 Delayed Quote.-48.01%
JOHNSON & JOHNSON 1.46% 182.29 Delayed Quote.6.56%
MODERNA, INC. 0.71% 144.27 Delayed Quote.-43.20%
PFIZER, INC. 2.99% 51.59 Delayed Quote.-12.63%
All news about MODERNA, INC.
07:14aINSIDER SELL : Moderna
MT
06/26Moderna Seeks Swissmedic's Approval Extension For COVID-19 Jab Against Omicron
MT
06/25Pfizer says tweaked COVID-19 shots boost omicron protection
AQ
06/24INSIDER SELL : Moderna
MT
06/24Moderna COVID-19 shots now an option for older kids in US
AQ
06/24U.S. CDC backs Moderna's COVID vaccine for teens, older children
RE
06/24The next COVID booster shots will likely be updated for Omicron
RE
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
RE
06/24US Public Health Agency Advisers Recommend Moderna's COVID-19 Jab For Ages Six to 17
MT
06/24MODERNA, INC.(NASDAQGS : MRNA) added to Russell 1000 Value-Defensive Index
CI
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 079 M - -
Net income 2022 11 509 M - -
Net cash 2022 18 531 M - -
P/E ratio 2022 5,29x
Yield 2022 -
Capitalization 57 385 M 57 385 M -
EV / Sales 2022 1,76x
EV / Sales 2023 3,54x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 144,27 $
Average target price 213,67 $
Spread / Average Target 48,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371
ICON PUBLIC LIMITED COMPANY-28.76%17 936